Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein an Efflux Transporter on the Pharmacokinetics of Edoxaban an Oral Factor Xa Inhibitor

摘要

BackgroundEdoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure.